Complications of Cardiac Perforation and Lead Dislodgement with an MRI-Conditional Pacing Lead: A Korean Multi-Center Experience

Chang Hee Kwon,*a Jin Hee Choi,*a Jun Kim,a Joobji Hyun Lee,a Woo Seok Lee,a Yoo Ri Kim,a Soo Yong Lee,b Ki Won Whang,a Ji Hyun Yang,a Sung-Hwan Kim,c Yong-Seog Oh,d Kyoung-Min Park,e Gi-Byoung Nam,f Kee-Joon Choi,g and You-Ho Kimh

*Division of Cardiology, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea; aDivision of Cardiology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; bDivision of Cardiology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea; cDivision of Cardiology, Department of Internal Medicine, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea; dDivision of Cardiology, Department of Internal Medicine, University Yangsan Hospital, Yangsan, Korea; eDivision of Cardiology, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea; fDivision of Cardiology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea; gDivision of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

aChang Hee Kwon and Jin Hee Choi contributed equally to this work.

Received: 26 January 2016
Accepted: 2 June 2016

Use of magnetic resonance imaging (MRI) is rapidly increasing for diagnostic purposes in many fields (e.g., the brain, spinal cord, and musculoskeletal system). About 50-70% of the patients with cardiac implantable electronic device (CIED) will be estimated to have an indication for a MRI over the lifetime of the device (1). However, MRI has been traditionally contraindicated in patients with CIED owing to potential risk to the patient or device (2,3).

Recently, MRI conditional pacemaker system (EnRhythm MRI SureScan implantable pulse generator and CapSureFix MRI lead [5086 lead], Medtronic, Inc., Minneapolis, MN, USA) has been reported to be associated with increased cardiac perforation and lead dislodgement. This study aimed to compare the incidence of cardiac perforation and lead dislodgement within 30 days after pacemaker implantation between 5086 MRI lead and previous Medtronic CapSureFix Novus 5076 non-MRI pacing lead. This was a nationwide, multicenter retrospective study in which we compared the incidence of adverse events between 277 patients implanted with 5086 lead and 205 patients implanted with 5076 lead between March 2009 and September 2014. Cardiac perforation within 30 days of pacemaker implantation occurred in 4 patients (1.4%) with the 5086 lead and in no patient with the 5076 lead (P = 0.084). Lead dislodgement occurred in 8 patients (2.9%) with the 5086 lead and in 5 patients (2.4%) with the 5076 lead (P = 0.764). On multivariate logistic regression analysis, age was significantly associated with cardiac perforation. Congestive heart failure and implantation of right atrial (RA) lead at RA free wall or septum were significant factors for the incidence of lead dislodgement and lead revision. The incidence of cardiac perforation and lead dislodgement were not statistically different between the patients with 5086 lead and the patients with 5076 lead. However, careful attention for cardiac perforation may be needed when using the 5086 MRI lead, especially in elderly patients.

Keywords: Complications; Magnetic Resonance Imaging; Pacemaker; Cardiac Perforation

INTRODUCTION

Use of magnetic resonance imaging (MRI) is rapidly increasing for diagnostic purposes in many fields (e.g., the brain, spinal cord, and musculoskeletal system). About 50-70% of the patients with cardiac implantable electronic device (CIED) will be estimated to have an indication for a MRI over the lifetime of the device (1). However, MRI has been traditionally contraindicated in patients with CIED owing to potential risk to the patient or device (2,3).

Recently, MRI conditional pacemaker system (EnRhythm MRI SureScan implantable pulse generator and CapSureFix MRI lead [5086 lead], Medtronic, Inc., Minneapolis, MN, USA) showed no adverse effect on either the patient or the pacemaker system in a magnetic resonance environment (4). Based on these results, this Medtronic pacing system became the first MRI conditional pacing system in the United States approved by the Food and Drug Administration (FDA) (5).

The 5086 MRI lead was modified to reduce radiofrequency lead tip heating. These modifications resulted in the larger diameter and greater stiffness of the leads compared to the conventional Medtronic CapSureFix Novus 5076 non-MRI pacing lead (5076 lead). As a result, the 5086 lead has been reported to be associated with increased cardiac perforation and lead dislodgement (6-8). However, these results were not consistent with previous results (4,9,10). Moreover, to our knowledge, there was no Asian data on the safety of the 5086 lead. Therefore, this study aimed to compare cardiac perforation and lead dislodgement between the 5086 lead and the previous 5076 lead.
MATERIALS AND METHODS

Patient population
This was a multicenter retrospective study, which included 482 consecutive patients who underwent permanent pacemaker implantation with the 5086 lead (277 patients, 57.5%) or the 5076 lead (205 patients, 42.5%) between March 2009 and September 2014. The choice of the pacing lead depended on the operator’s discretion. All patients received dual atrial and ventricular pacing leads for atrioventricular block (n = 241, 50.0%), sick sinus syndrome (n = 230, 47.7%), and both (n = 11, 2.3%). The study populations meet inclusion criteria. Inclusion criteria were: 1) patients older than 18 years of age, 2) patients without known pericardial effusion and an additional pacing lead implanted within 30 days prior to implant, and 3) patients who participated in follow-up for 30 days after implant. Clinical data was retrospectively analyzed.

Lead characteristics
Both 5086 and 5076 leads are steroid-eluting with screw-in active fixation. Lead polarity (bipolar), standard length (52 cm and 58 cm), lead tip surface (4.2 mm²), ring electrode (22 mm²), tip-ring spacing (10 mm), and inner and outer insulation (silicone) are identical in both leads. The differences between two leads are inner coil (2 filars in 5086 lead vs. 4 filars in 5076 lead) and lead body diameter (2.3 mm in 5086 lead vs. 2.0 mm in 5076 lead).

Endpoint
The primary endpoint was the incidence of cardiac perforation within 30 days after pacemaker implantation. Cardiac perforation was defined as a radiographic evidence of excursion of the pacing lead into the pericardial sac, and abnormal echocardiography indicative of a perforation, the accumulation of fluid in the pericardium with cardiac tamponade. The second endpoint was lead dislodgement within 30 days of implantation. Definition of the lead dislodgement was the movement of the pacing lead from its originally implanted position resulting in elevated pacing thresholds or a decrease in sensing (11).

Chest radiography was performed immediately after pacemaker implantation, and was followed daily before hospital discharge and first follow-up visit within 30 days. The post-procedural echocardiography was performed by physician’s discretion depending on patient’s symptom (chest pain/discomfort or dyspnea) and hemodynamic instability, newly developed cardiomegaly on chest radiography, and so on.

Statistical analysis
Statistical analysis was performed using SPSS version 21 (SPSS Inc., Chicago, IL, USA). Baseline characteristics are expressed as mean ± standard deviation (SD) for continuous variables and as frequencies with percentages for categorical variables. Continuous variables were compared using Student’s t-tests, and categorical variables were compared using χ² test or Fisher’s exact tests. Comparisons of the primary and secondary endpoints between two groups were analyzed by χ² test or Fisher’s exact tests. A logistic regression analysis was conducted to identify potential predictors for lead complications. All variables with P values < 0.10 in univariate analysis were subjected to multivariate analysis. A P value < 0.05 was considered statistically significant.

RESULTS

Baseline characteristics
A total of 482 patients (mean age, 66.6 ± 12.9 years; 209 men [43.4%]) were enrolled. Baseline characteristics of the study patients according to the type of pacing lead are summarized in Table 1. Procedure time was significantly longer when using the 5086 lead than that for the 5076 lead. The procedure time (113.4 ± 43.4 minutes) for the 5086 lead was still longer than that (99.6 ± 46.5 minutes) for the 5076 lead (P = 0.003) after excluding two patients (mean time = 183 minutes) who developed cardiac tamponade during procedure.

Endpoints
Four patients (0.8%) showed evidence of cardiac perforation as pericardial effusion with cardiac tamponade, necessitating only pericardiocentesis in 3 patients, and both pericardiocentesis and lead revision in one patient (Table 2). There was no one who showed a radiographic evidence of excursion of the pacing lead into the pericardial sac. All patients with cardiac perforation received the 5086 lead. Mean age of patients with cardiac perforation was 84 ± 3.5 years. Fellow trainee operated procedure in 122 cases (59.5%) of 5076 lead and in 193 cases (69.7%) of 5086 lead. In four cases of cardiac perforation, three patients were operated by fellow trainee and one patient by staff.

Characteristics of patients with cardiac perforation were described in Table 3. Two cases of cardiac perforation developed during the procedure of device implantation, and received pericardiocentesis promptly. One of them underwent lead revision the next day. One patient showed evidence of cardiac perforation on the day after device implantation. Cardiac perforation in the last patient was found two days after implantation. Any patient with cardiac perforation did not receive either anti-
platelet or anticoagulant earlier.

Lead dislodgement developed in 13 (2.7%) of all patients with device implantation. The incidence of lead dislodgement was not significantly different between the 5086 and 5076 leads (Table 2). The incidence of lead dislodgement by fellow trainee was similar between 5076 lead (5 cases, 4.0%) and 5086 lead (8 cases, 4.1%). The right atrial (RA) lead dislodged in 10 patients, the right ventricular (RV) lead in 1, and both RA and RV leads

### Table 1. Baseline characteristics of the study patients

| Parameters                  | 5086 MRI lead (n = 277) | 5076 non-MRI lead (n = 205) | P value |
|-----------------------------|-------------------------|-----------------------------|---------|
| Age, yr                     | 66.4 ± 12.8             | 66.9 ± 12.8                 | 0.676   |
| Male, No. (%)               | 133 (48.0)              | 76 (37.1)                   | 0.020   |
| Body mass index, kg/m²      | 23.9 ± 3.1              | 24.2 ± 3.1                  | 0.349   |
| Body surface area, m²       | 1.6 ± 0.2               | 1.6 ± 0.2                   | 0.746   |
| Hypertension, No. (%)       | 123 (44.4)              | 107 (52.2)                  | 0.097   |
| Diabetes mellitus, No. (%)  | 48 (17.4)               | 46 (22.4)                   | 0.229   |
| Atrial fibrillation, No. (%)| 73 (26.4)               | 46 (22.4)                   | 0.338   |
| Congestive heart failure, No. (%) | 12 (4.3)         | 7 (3.4)                      | 0.813   |
| Cardiac tamponade, No. (%)  | 36 (13.0)               | 28 (13.8)                   | 0.892   |
| Cardiac tamponade requiring lead revision | 62 (22.5)      | 33 (16.1)                   | 0.105   |
| RA lead at RAA, No. (%)     | 52 (18.8)               | 29 (14.1)                   | 0.178   |
| LV EF, %                    | 59.9 ± 10.5             | 61.3 ± 9.9                  | 0.149   |
| LA diameter, mm             | 40.6 ± 8.1              | 42.1 ± 9.7                  | 0.077   |
| LV ESD, mm                  | 31.2 ± 6.4              | 31.1 ± 6.0                  | 0.859   |
| LV EDD, mm                  | 49.7 ± 7.1              | 50.9 ± 7.1                  | 0.407   |
| TR grade                    | 0 (0.1)                 | 0 (0.1)                     | 0.489   |
| Anti-platelets, No. (%)     | 79 (35.6)               | 74 (40.0)                   | 0.360   |
| Aspirin, No. (%)            | 60 (27.0)               | 51 (27.6)                   | 0.615   |
| Clopidogrel, No. (%)        | 8 (3.6)                 | 10 (5.4)                    | 0.499   |
| Dual, No. (%)               | 11 (5.0)                | 13 (7.0)                    | 0.499   |
| Oral anticoagulants, No. (%)| 50 (22.5)               | 24 (13.0)                   | 0.013   |
| Warfarin, No. (%)           | 42 (18.9)               | 24 (36.4)                   | 0.019   |
| Dabigatran, No. (%)         | 8 (3.6)                 | 0 (0.0)                     |        |
| Rivaroxaban, No. (%)        | 7 (3.2)                 | 0 (0.0)                     |        |
| Lead position               |                         |                            |         |
| RA lead at RAA, No. (%)     | 269 (97.1)              | 199 (97.5)                  | 0.770   |
| RV lead at RVA, No. (%)     | 177 (63.9)              | 165 (80.5)                  | <0.001  |
| Procedure time, min         | 114.2 ± 44.0            | 99.6 ± 46.5                 | 0.002   |

Data are expressed as mean ± SD or as a number (percentage or interquartile).

LA, left atrium; LV EDD, left ventricle end-diastolic dimension; LV ESD, left ventricle end-systolic dimension; LV EF, left ventricle ejection fraction; MRI, magnetic resonance imaging; RA, right atrium; RAA, right atrial appendage; RV, right ventricle; RVA, right ventricular apex; TR, tricuspid regurgitation.

### Table 2. Comparisons of cardiac perforation and lead dislodgement in the first 30 days between 5086 MRI lead and 5076 non-MRI lead

| Events                              | 5086 MRI lead (n = 277) | 5076 non-MRI lead (n = 205) | P value |
|-------------------------------------|-------------------------|-----------------------------|---------|
| No. of events                       | Event rate, %           | No. of events               | Event rate, % |       |
| Total                               | 12                      | 4.3                         | 5        | 2.4   | 0.265 |
| Cardiac perforation                 |                         |                             | 0        | 0     | 0.140*|
| Cardiac tamponade requiring lead revision |             |                             | 0        | 0     | 0.389 |
| Cardiac tamponade with pericardiocentesis |             |                             | 0        | 0     | 0.140*|
| Lead dislodgement                   |                         |                             | 8        | 2.9   | 0.764 |
| RA lead                             | 7                       | 2.5                         | 5        | 2.4   | 0.951 |
| RV lead                             | 3                       | 1.1                         | 1        | 0.5   | 0.265*|

P value was calculated by chi-square χ² test or *Fisher’s exact tests.

*Fisher’s exact tests.

### Table 3. Characteristics of patients with cardiac perforation

| Patient | Institute | Age, yr | Sex | Leads | Days postimplant | Operator | RV lead position | Anticoagulants | Pericardiocentesis | Lead revision |
|---------|-----------|---------|-----|-------|------------------|----------|------------------|---------------|-------------------|---------------|
| 1       | A         | 83      | M   | 5086  | 0                | Fellow   | RV apex          | No            | Yes               | Yes           |
| 2       | A         | 81      | F   | 5086  | 2                | Fellow   | RV apex          | No            | Yes               | No            |
| 3       | A         | 83      | F   | 5086  | 0                | Fellow   | RV apex          | No            | Yes               | No            |
| 4       | B         | 89      | F   | 5086  | 0                | Staff    | Mid septum       | No            | Yes               | No            |
in 2. Almost all (11 patients) dislodgement was noticed within 24 hours of implantation. In the remaining two cases, dislodgement was noticed on post-implantation day 3 and 4. All patients with lead dislodgement underwent lead revision. The rate of lead revision within 30 days of implantation was not significantly different between the 5086 (9 patients [3.2%]) and 5076 leads (5 patients [2.4%]) (P = 0.601).

Predictors for lead complications
We performed logistic regression analysis to identify significant predictors of lead complications (Table 4). Age was only significant predictor for cardiac perforation in multivariate analysis. Congestive heart failure and implantation of RA lead at RA free wall or septum were significant predictors of lead dislodgement and lead revision. Left ventricular ejection fraction was significantly different between the patients with lead dislodgement and those without (lead dislodgement: 53.3% ± 10.2% vs. no lead dislodgement: 60.7% ± 10.2%, P = 0.011). However, left ventricular systolic function was not significant predictor for lead dislodgement after adjusting congestive heart failure. The 5086 lead was not associated with lead complications.

DISCUSSION
We compared the incidence of acute complications related to pacemaker lead between the 5086 and 5076 leads. The major findings of the present study are as follows: 1) all cardiac perforation occurred when using the 5086 lead (4 patients, 1.4%), but there was no statistically significant difference with the 5076 lead; 2) the incidences of lead dislodgement (2.9% vs. 2.4%, P = 0.764) and lead revision (3.2% vs. 2.4%, P = 0.601) were not significantly different between the 5086 and 5076 leads; 3) age was only significant predictor of cardiac perforation, and congestive heart failure and implantation of RA lead at the outside of RA appendage were significant predictors of lead dislodgement and revision.

Lead dislodgement and cardiac perforation/pericardial effusion were most common lead related complications of pacemaker implantation. The published incidence of lead dislodgement varies from 0.5% to 4.0% (12-16). Atrial lead dislodgement is more common than ventricular lead dislodgement. The incidence of cardiac perforation and/or pericardial effusion after pacemaker implantation is reported between 0.5% and 2.0%, but nowadays it is usually lower than 1% (17-21). In the present study, the incidence of lead dislodgement and cardiac perforation was 2.7% and 0.8%, respectively, which was consistent with previous results.

The rates of cardiac perforation (1.4%) and lead dislodgement (2.9%) using the 5086 lead in our study were consistent with those in previous two large prospective randomized studies using the 5086 lead. In EnRhythm MRI study, cardiac perforation and/or pericardial effusion developed in 5 of 467 patients (1.0%), and lead dislodgement occurred in 17 of 467 patients (3.6%) (4). In the Advisa MRI study, the number patients with cardiac perforation and/or pericardial effusion and lead dislodgement was 5 (1.9%) and 11 (4.1%) out of total 266 patients, respectively (10). However, recent two studies reported that the incidence of cardiac perforation and/or pericardial effusion, and lead dislodgement was significantly higher with the 5086 lead. Elmouchi et al. (6) reported that 5 (7.7%) of 65 patients developed cardiac perforation and/or pericardial effusion, and 4 (6.2%) patients showed lead dislodgement. Acha et al. (8) showed that there were 4 (5.5%) cases of cardiac perforation and 2 (2.8%) of lead dislodgement among the 72 patients. The reason for these different results is not clear, but might be explained by the differences of study populations, implant
techniques, and learning curve period of the 5086 lead between the centers.

The two abovementioned studies showed that the incidence of cardiac perforation and/or pericardial effusion was significantly higher with the 5086 lead than that with the previous 5076 lead (6,8). In the present study, all cardiac perforation was developed using the 5086 lead, but there was no statistical difference with the 5076 lead. On the other hand, a recent retrospective cohort analysis revealed that a cardiac perforation was similar between the 5086 (0.6%) and the 5076 (0.6%) leads; however, there were more lead dislodgements in the 5086 lead (2.6%) than in the 5076 lead (0.6%) ($P = 0.054$) over the first 30 days (7). Moreover, there was a discrepancy in the difference in cardiac perforation between the 5086 and 5076 leads, in that the 5086 lead may have greater risk of cardiac perforation than the 5076 lead. The 5086 lead was generated from multiple system design modifications of the previous 5076 lead. These modifications include decreasing the number of lead filars, increasing the filament diameter, and increasing the thickness of the inner coil with its number of turns (4). As a result of these modifications, 5086 lead is stiffer and heavier with a larger outer lead diameter (2.3 mm vs. 2.0 mm) and has unusual horizontal pitch of bipolar conductor compared to that of the 5076 lead. Consequently, the 5086 lead has been required to increase the maximum number of helix rotations for atrial and ventricular lead implantation (10). The increased stiffness and the heaviness of the 5086 lead were suggested as a possibly responsible for the increased cardiac perforation (6).

The predictors of cardiac perforation have not been well defined. Previous studies reported female sex, active fixation leads, use of temporary pacemaker, steroids as significant predictors of cardiac perforation and/or pericardial effusion (16,17,19,21). However, the present study revealed that old age is the only significant predictor of cardiac perforation. The influence of aging on acute complication is debated. Old age was reported to be associated with an increased incidence of pneumothorax (12). However, large cohort studies did not show a relation between age and acute complications (22,23). In addition, congestive heart failure and implantation of RA lead at the areas (free wall or septum) other than the RA appendage are significant predictors of lead dislodgement and revision. Therefore, careful attention for cardiac perforation and/or lead dislodgement is required regardless of type of pacemaker lead when performing this procedure in old patients with congestive heart failure.

The management of cardiac perforation and/or pericardial effusion includes close monitoring, pericardiocentesis, lead revision, and surgery. Surgery requirement has been reported between 0% and 75% (17-21). However, Laborderie et al. (20) reported that perforated leads can safely be removed under fluoroscopic guidance, with surgical backup support and close monitoring. In the present study, no patient required surgical intervention, but all patients received percutaneous pericardial drainage, and one patient required lead revision. Therefore, if pericardial effusion shows tamponade physiology, pericardiocentesis can be preferred over surgical intervention. In addition, if capture and sensing values of perforated leads are stable, close monitoring also can be preferred over lead revision or surgery.

The present study was a retrospective multicenter observational, and thus, had inherent limitations. Especially, the implant period was different between the 5086 and 5076 leads because the 5086 lead was introduced into the market more recently. All physicians had years of experience implanting the previous 5076 lead, and thus, might have experienced a learning curve with the handling of the new 5086 lead. However, cardiac perforation and lead dislodgement rates were spread out through the study period. Even the present study had numerous limitations, such as lack of data on the incidence of acute complications including lead dislodgement and cardiac perforation with the 5086 and 5076 leads in an Asian population.

In conclusion, the incidence of cardiac perforation and lead dislodgement within 30 days after pacemaker implantation were not statistically different between the 5086 and 5076 leads. However, because all cardiac perforation occurred when using the 5086 lead, meticulous attention is required when using the 5086 lead, especially in elderly patients.

DISCLOSURE

The authors have no potential conflicts of interest to disclose.

AUTHOR CONTRIBUTION

Conception and design: Kim J, Nam GB, Choi KJ, Kim YH. Acquisition of data: Kwon CH, Choi JH, Jo U, Lee JH, Lee WS, Kim YR, Lee SY, Whang KW, Yang J, Kim SH, Oh YS, Park KM. Analysis and interpretation of data: Kwon CH, Choi JH, Kim J. Manuscript preparation: Kwon CH, Choi JH. Revision of manuscript: Kwon CH, Kim J. Manuscript approval: all authors.

ORCID

Chang Hee Kwon http://orcid.org/0000-0001-8716-1146
Jin Hee Choi http://orcid.org/0000-0003-2774-3851
Jun Kim http://orcid.org/0000-0002-3573-638X
Uk Jo http://orcid.org/0000-0001-8860-851X
Ji Hyun Lee http://orcid.org/0000-0002-7162-1248
Woo Seok Lee http://orcid.org/0000-0003-0250-1266
Yoo Ri Kim http://orcid.org/0000-0003-4218-6424
Soo Yong Lee http://orcid.org/0000-0002-1140-0910
Ki Won Whang http://orcid.org/0000-0002-1372-330X
REFERENCES

1. Kalin R, Stanton MS. Current clinical issues for MRI scanning of pacemaker and defibrillator patients. *Pacing Clin Electrophysiol* 2005; 28: 326-8.

2. Levine GN, Gomes AS, Arai AE, Bluemke DA, Flamm SD, Kanal E, Manning WI, Martin ET, Smith JM, Wilke N, et al. Safety of magnetic resonance imaging in patients with cardiovascular devices: an American Heart Association scientific statement from the Committee on Diagnostic and Interventional Cardiac Catheterization, Council on Clinical Cardiology, and the Council on Cardiovascular Radiology and Intervention: endorsed by the American College of Cardiology Foundation, the North American Society for Cardiac Imaging, and the Society for Cardiovascular Magnetic Resonance. *Circulation* 2007; 116: 2878-91.

3. Roguin A, Schwitter J, Vahlhaus C, Lombardi M, Brugada J, Vardas P, Auricchio A, Priori S, Sommer T. Magnetic resonance imaging in individuals with cardiovascular implantable electronic devices. *europace* 2008; 10: 336-46.

4. Wilkoff BL, Bello D, Taborsky M, Vymazal J, Kanal E, Heuer H, Hecking K, Johnson WB, Young W, Ramza B, et al. Magnetic resonance imaging in patients with a pacemaker system designed for the magnetic resonance environment. *Heart Rhythm* 2011; 8: 65-73.

5. Mitka M. First MRI-safe pacemaker receives conditional approval from FDA. *JAMA* 2011; 305: 985-6.

6. Elmouchi DA, Rosema S, Vanooosterhout SM, Khan M, Davis AT, Gauri AJ, Finta B, Woolf AK, Challouf NT. Cardiac perforation and lead dislodgement after implantation of a MR-conditional pacing lead: a single-center experience. *Pacing Clin Electrophysiol* 2014; 37: 4-10.

7. Rickard J, Taborsky M, Bello D, Johnson WB, Ramza B, Chang Y, Wilkoff BL. Short- and long-term electrical performance of the 5086MR pacing lead. *Heart Rhythm* 2014; 11: 222-9.

8. Acha MR, Keaney II, Lubitz SA, Milan DJ, Mansour M, Heist KE, Ptaszek LM, Singh JP, Blendeda D, Mela T. Increased perforation risk with an MRI-conditional pacing lead: a single-center experience. *Pacing Clin Electrophysiol* 2015; 38: 334-42.

9. Forleo GB, Santini L, Della Rocca DG, Romano V, Papavasileiou LP, Maglia-no G, Sgueglia M, Romeo F. Safety and efficacy of a new magnetic resonance imaging-compatible pacing system: early results of a prospective comparison with conventional dual-chamber implant outcomes. *Heart Rhythm* 2010; 7: 750-4.

10. Gimbel JR, Bello D, Schmitt M, Mekely B, Schwitter J, Hayes DL, Sommer T, Schloss EI, Chang Y, Willey S, et al. Randomized trial of pacemaker and lead system for safe scanning at 1.5 Tesla. *Heart Rhythm* 2013; 10: 685-91.

11. Reddy VY, Exner DV, Cantillon DJ, Doshi R, Bunch TJ, Tomassoni GF, Friedman PA, Estes NA 3rd, Jp J, Niazi I, et al. Percutaneous implantation of an entirely intracardiac leadless pacemaker. *N Engl J Med* 2015; 373: 1125-35.

12. Link MS, Estes NA 3rd, Griffin JJ, Wang PJ, Maloney JD, Kirchhoff JB, Mitchell GE, Orav J, Goldman L, Lamas GA. Complications of dual chamber pacemaker implantation in the elderly. Pacemaker Selection in the Elderly (PASE) Investigators. *J Interv Card Electrophysiol* 1998; 2: 175-9.

13. Ghani A, Delnoy PP, Ramdat Misier AR, Smit JF, Adyaman A, Ottervanger JP, Elvan A. Incidence of lead dislodgement, malfunction and perforation during the first year following device implantation. *Neth Heart J* 2014; 22: 286-91.

14. Armaganian LV, Toff WD, Nielsen JC, Andersen HR, Connolly SJ, Ellenbogen KA, Healey JS. Are elderly patients at increased risk of complications following pacemaker implantation? A meta-analysis of randomized trials. *Pacing Clin Electrophysiol* 2012; 35: 131-4.

15. Pakarinen S, Oikarinen L, Toivonen L. Short-term implantation-related complications of cardiac rhythm management device therapy: a retrospective single-centre 1-year survey. *europace* 2010; 12: 103-8.

16. Udo EO, Ziaithoff NP, van Hemel NM, de Cock CC, Hendriks T, Doeven-dans PA, Mooms KG. Incidence and predictors of short- and long-term complications in pacemaker therapy: the FOLLOWPACE study. *Heart Rhythm* 2012; 9: 728-35.

17. Mahapatra S, Bybee KA, Bunch TJ, Espinosa RE, Sinak LJ, McGoon MD, Hayes DL. Incidence and predictors of cardiac perforation after permanent pacemaker placement. *Heart Rhythm* 2005; 2: 907-11.

18. Migliore E, Zorzi A, Bertaglia E, Leoni L, Siciliano M, De Lazzari M, Ignatiuk B, Veronese M, Verlato R, Tarantini G, et al. Incidence, management, and prevention of right ventricular perforation by pacemaker and implantable cardioverter defibrillator leads. *Pacing Clin Electrophysiol* 2014; 37: 1602-9.

19. Sier rivalry M, Przybylski A, Maciag A, Syska P, Pytkowski M, Lewandowski M, Kowalik I, Firek B, Kolsut P, Reilga G, et al. Subacute cardiac perforations associated with active fixation leads. *Europace* 2009; 11: 206-12.

20. Laborde J, Barandon L, Ploux S, Deplagne A, Mokrani B, Reuter S, Le Gal F, Jais P, Haissaguerre M, Clementy J, et al. Management of subacute and delayed right ventricular perforation with a pacing or an implantable cardioverter-defibrillator lead. *Am J Cardiol* 2008; 102: 1352-5.

21. Ohlow MA, Lauer B, Brunelli M, Geller JC. Incidence and predictors of pericardial effusion after permanent heart rhythm device implantation: prospective evaluation of 968 consecutive patients. *Circ J* 2013; 77: 975-81.

22. Ellenbogen KA, Hellkamp AS, Wilkoff BL, Camunãs JL, Love JC, Hadijs TA, Lee KL, Lamas GA. Complications arising after implantation of DDD pacemakers: the MOST experience. *Am J Cardiol* 2003; 92: 740-1.

23. Novak B, Mielczwitz B; Expert Committee Pacemaker, Institute of Quality Assurance Hessen. Effects of increasing age onto procedural parameters in pacemaker implantation; results of an obligatory external quality control program. *europace* 2009; 11: 75-9.